Newswire (Published: Tuesday, April 11, 2017, Received: Friday, April 7, 2017, 2:33:36 PM CDT)
Word Count: 571
Findings from University of Illinois Yields New Data on Prostate Cancer (Predicting Time From Metastasis to Overall Survival in Castration-Resistant Prostate Cancer: Results From SEARCH)
By a News Reporter-Staff News Editor at Cancer Weekly -- Investigators publish new report on Oncology - Prostate Cancer. According to news reporting out of Chicago, Illinois, by NewsRx editors, research stated, "We investigated the predictors of time from metastatic castration-resistant prostate cancer (mCRPC) to all cause mortality among patients treated at Veteran Affairs hospitals. We found that age, more remote year of mCRPC, greater number of bone metastasis, higher prostate-specific antigen levels, and shorter prostate specific antigen doubling time at mCRPC diagnosis were associated with shorter overall survival."
Financial supporters for this research include National Institute of Health (NIH), NIH (see also Oncology - Prostate Cancer).
Our news journalists obtained a quote from the research from the University of Illinois, "A nomogram was generated yielding good concordance and calibration. To identify the predictors of time from initial diagnosis of metastatic castration-resistance prostate cancer (mCRPC) to all-cause death within the Shared Equal Access Regional Cancer Hospital cohort. We performed a retrospective analysis of 205 mCRPC men. Overall survival was estimated and plotted using the Kaplan-Meier method. The uni- and multivariable overall survival predictors were evaluated with the Cox proportional hazards model. A nomogram was generated to predict overall survival at 1, 2, 3, and 5 years after mCRPC. Concordance index and calibration plot were obtained. A total of 170 men (83%) died over a median followup of 41 months. In univariable analysis, older age, more remote year of mCRPC, nonblack race, greater number of bone metastasis, higher prostate-specific antigen (PSA) levels, shorter PSA doubling time, and faster PSA velocity at mCRPC diagnosis were significantly associated with shorter overall survival (all P< .05). In multivariable analysis, older age, more remote year of mCRPC, greater number of bone metastasis, higher PSA levels, and shorter PSA doubling time at mCRPC diagnosis remained significantly associated with shorter overall survival (all P< .05). On the basis of these variables, a nomogram was generated, yielding a concordance index of 0.67 and good calibration."
According to the news editors, the research concluded: "The use of clinical parameter such as age, disease burden, and PSA levels and kinetics can be used to estimate overall survival in mCRPC patients."
For more information on this research see: Predicting Time From Metastasis to Overall Survival in Castration-Resistant Prostate Cancer: Results From SEARCH. Clinical Genitourinary Cancer, 2017;15(1):60-66. Clinical Genitourinary Cancer can be contacted at: Cig Media Group, Lp, 3500 Maple Avenue, Ste 750, Dallas, TX 75219-3931, USA. (Elsevier - www.elsevier.com; Clinical Genitourinary Cancer - www.journals.elsevier.com/clinical-genitourinary-cancer/)
Our news journalists report that additional information may be obtained by contacting D.M. Moreira, University of Illinois, Dept. of Urol, Chicago, IL, United States. Additional authors for this research include L.E. Howard, K.N. Sourbeer, H.S. Amarasekara, L.C. Chow, D.C. Cockrell, C.L. Pratson, B.T. Hanyok, W.J. Aronson, C.J. Kane, M.K. Terris, C.L. Amling, M.R. Cooperberg and S.J. Freedland.
Keywords for this news article include: Chicago, Illinois, United States, North and Central America, Prostate-Specific Antigen, Enzymes and Coenzymes, Prostatic Neoplasms, Prostate Cancer, Bone Research, Oncology, University of Illinois.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC
University of Illinois
Science and Technology
Health and Wellness
Medical Conditions and Diseases
Men's Health Issues